In patients with stage III colorectal cancer (CRC) who have undergone potentially curative resection, adjuvant treatment with 6 months' of 5-fluorouracil (5-FU) plus folinic acid (FA) is generally accepted as standard treatment and leads to a 5% to 10% improvement in absolute survival when compared with a no-chemotherapy control. In stage II CRC, the benefit of adjuvant chemotherapy has yet to ...

Background/Aim Currently, it has been proposed that combination of 5-fluorouracil (5FU) with inhibitors of the mitogen-activated protein kinases (MAPKs) signaling pathway might enhance the efficacy of 5FU-based chemotherapy in colon cancer. Our study aimed to investigate an impact of TWIST1 silencing on the sensitivity of cancer cells to 5FU and selected MAPK inhibitors. Materials and Methods...

To understand one of the mechanisms of resistance to chemoradiation in colon cancer cells, we investigated whether 5-fluorouracil (5-FU) mediated the expression of epidermal growth factor receptor (EGFR) and modified repair of radiation-induced DNA damage, especially in a p53 independent pathway. Cytotoxicity was determined for 5-FU combined with radiation for three colon cancer cell lines that...

The present treatment of colon cancer is based on 5-fluorouracil (5-FU). Despite promising results of combining leucovorin or levamisole with 5-FU, the 5-year survival rate of patients with advanced colon cancer has not increased significantly. Colon tumors in vitro have been shown previously to have an elevated requirement for methionine, suggesting a new therapeutic target. In this study, tar...

Background: To describe the patient characteristics and usage pattern of biosimilar bevacizumab for treatment metastatic colorectal cancer (mCRC) in India.Methods: This real-world, retrospective analysis included adult patients receiving between April 2021 March 2022.Results: A total 1125 with mCRC who received bevacizumab-based chemotherapy were included. The mean age at diagnosis was 57.8 yea...

two common single nucleotide polymorphisms (snps) of the human tlr4 gene, namely asp299gly (d299g) and thr399ile (t399i), have been shown to impair the ability of certain individuals to respond properly to tlr4 ligands. 5-fluorouracil (5-fu) is widely used for the treatment of patients with advanced colon cancers. the present study examined the impact of two common polymorphisms of the tlr4 gen...